ArticleAmerican journal of translational research2025
Development and evaluation of a predictive model for postoperative recurrence and metastasis in breast cancer using an artificial intelligence ultrasound breast system.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the feasibility and efficacy of developing a predictive model for postoperative recurrence and metastasis in breast cancer using the Artificial Intelligence Ultrasound Breast System (AIUBS).
methodsA retrospective study was conducted with 120 breast cancer patients who underwent surgery between January 2022 and December 2023. Patients were divided into two groups based on postoperative outcomes: recurrence/metastasis (n = 58) and non-recurrence/non-metastasis (n = 62). Logistic regression was used to identify independent predictors, and a nomogram model was constructed. Model performance was assessed using Receiver Operating Characteristic curves, calibration curves, and decision curve analysis (DCA). The optimal cutoff value was determined through confusion matrix analysis.
resultsUnivariate analysis identified lymph node metastasis (OR = 8.17, 95% CI: 3.51-18.99), estrogen receptor (ER) status (OR = 0.46, 95% CI: 0.21-0.99), and human epidermal growth factor receptor 2 status (OR = 5.32, 95% CI: 2.32-12.22) as significant predictors. Multivariate analysis confirmed lymph node metastasis (OR = 8.81, 95% CI: 3.68-21.07) and ER status (OR = 0.39, 95% CI: 0.16-0.94) as independent predictors. The nomogram model demonstrated an Area Under the Curve of 0.77 (95% CI: 0.68-0.85). The optimal cutoff value, derived from confusion matrix analysis, was 0.572, confirming the model's clinical utility.
conclusionThe AIUBS-based predictive model for postoperative recurrence and metastasis in breast cancer demonstrates high predictive accuracy and clinical utility, providing valuable support for personalized treatment and follow-up decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.